Adjuvant justification study of candidate malaria vaccines (257049), administered according to a 0, 1, 2 months schedule

Trial Profile

Adjuvant justification study of candidate malaria vaccines (257049), administered according to a 0, 1, 2 months schedule

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Apr 2017

At a glance

  • Drugs GSK 257049 (Primary) ; AS01B; AS02
  • Indications Falciparum malaria
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 23 Oct 2008 Actual start date changed from Apr 2007 to Mar 2007 as reported by ClinicalTrials.gov.
    • 11 May 2008 Status changed from in progress to completed.
    • 16 Apr 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top